Gilead Sciences (GILD) Non Operating Income (2009 - 2026)

Gilead Sciences (GILD) has reported Non Operating Income for 18 consecutive years, with $235.0 million the latest figure, recorded in Q1 2026.

• Non Operating Income for Q1 2026 came in at $235.0 million, up 171.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 430.34% YoY), and the FY2025 annual result was $798.0 million, up 13200.0% from the prior year.
• Non Operating Income was $235.0 million for Q1 2026 at Gilead Sciences, down from $349.0 million in the prior quarter.
• Over five years, Non Operating Income peaked at $569.0 million in Q3 2025 and troughed at -$355.0 million in Q2 2024.
• Average Non Operating Income over 5 years is $38.7 million, with a median of -$10.0 million recorded in 2022.
• Year-over-year, Non Operating Income jumped 3030.0% in 2023 and sank 460.44% in 2025.
• Over 5 years, Non Operating Income stood at -$10.0 million in 2022, then surged by 3030.0% to $293.0 million in 2023, then tumbled by 111.95% to -$35.0 million in 2024, then jumped by 1097.14% to $349.0 million in 2025, then sank by 32.66% to $235.0 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $235.0 million in Q1 2026, $349.0 million in Q4 2025, and $569.0 million in Q3 2025.